<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

Biotech Growth Stage (pre-series B)


Hosted by:

Otsuka Pharmaceutical 300x

Designed exclusively for post series A, pre-series B therapeutic biotech companies.

 

10:30 Arctoris Logo

10:45 Ochre Bio Logo

 


11:00 EnteroBiotix Logo

 


11:15 VasoDynamics Logo

 


11:30 Versameb Logo

 


11:45

Pharma Partnering With Otsuka Pharmaceutical

  • Otsuka: 100 years of Innovation for Better Health Worldwide
  • Leveraging Internal Capabilities and Collaborations to Build a Global Pharma Business
  • Why Collaborate with Otsuka in Neuroscience, Kidney or Autoimmune Diseases?

Sahil Kirpekar, MD, MPhil, Head of Business Development, Otsuka Pharmaceutical
Armin Rump, Ph.D., Associate Director, Global Business Development, Otsuka Pharmaceutical

Sahil Kirpekar, Head of Business Development, OtsukaArmin Rump, Associate Director, Global Business Development, Otsuka


12:00

Contact us to reserve


12:15 Scenic Biotech Logo

 


12:30 Azafaros Logo

 


12:45 Ixaka Logo

 


13:00 Lunac Therapeutics Logo

 


13:15 Augustine Therapeutics Logo

 


13:30 Rejuveron-1

 


13:45 Oxford Vacmedix Logo

 


14:00

Lenio Bio Logo

 


14:15

Combined Therapeutics Logo

 


14:30

Gadeta Logo

 


14:45

Glycostem Therapeutics Logo

 


15:00

CNS and the Market -- What is New in the Pipeline and in Deal Activity?

A few years ago, a “quiet revolution” was taking place in central nervous system (CNS) therapeutics: Companies large and small started to put more resources into CNS research, developing novel therapies for debilitating neurological and psychiatric diseases. The outcome of that development underpinned higher deal and investment activity. However, in the first half of 2022, CNS company stocks fell by 28%. Biotech and pharma company representatives as well as specialised investors will discuss the current state of affairs of CNS drug development: What’s on the horizon?

  • From rare neurological to large psychiatric indications. What are the most significant new developments in CNS therapeutics?
  • Progress in precision neuropsychiatry and biomarker development
  • What is next for CNS drugs? Predictions for the next 10 years

Moderator: Olga Krylova, Ph.D., Director, Global Business Development, Otsuka Pharmaceutical
Jenny Barnett
, CEO, Monument Tx

Olga Krylova, Director, Global Business Development, OtsukaJenny Barnett, CEO, Monument Tx


15:45 Aphaia Pharma Logo

 


16:00

bBHC STRI Logo

 


16:15

SOM Bio Logo

 


16:30

Aelin Therapeutics Logo

 


16:45

Actimed Therapeutics Logo

 


17:00

Dizlin Logo

 


17:15

Close of Investival Showcase


18:30

Lifestars Logo

Awards & Gala Dinner
- Separate ticket required
- Find out more

DOWNLOAD BROCHURE